Candriam Equities L Biotechnology Class I EUR Hedged Cap

Register to Unlock Ratings
Performance History31/03/2024
Growth of 1,000 (GBP) Advanced Graph
Candriam Equities L Biotechnology Class I EUR Hedged Cap
Fund25.6-8.7-0.12.51.0
+/-Cat-----
+/-B’mrk-----
 
Key Stats
NAV
25/04/2024
 EUR 1926.82
Day Change -1.38%
Morningstar Category™ Other Equity
ISIN LU1006082199
Fund Size (Mil)
25/04/2024
 USD 1441.67
Share Class Size (Mil)
25/04/2024
 EUR 20.54
Max Initial Charge -
Ongoing Charge
17/02/2023
  0.80%
Investment Objective: Candriam Equities L Biotechnology Class I EUR Hedged Cap
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund as set out below and defined in the section entitled Risk factors in the Prospectus.
Returns
Trailing Returns (GBP)25/04/2024
YTD-6.24
3 Years Annualised-2.44
5 Years Annualised5.01
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
Rudi Van den Eynde
06/04/2000
Linden Thomson
29/02/2024
Inception Date
04/12/2015
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USD-
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Candriam Equities L Biotechnology Class I EUR Hedged Cap29/02/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.180.0095.18
Bond0.000.000.00
Property0.000.000.00
Cash4.820.004.82
Other0.000.000.00
Top 5 Regions%
United States84.28
United Kingdom5.07
Eurozone3.98
Europe - ex Euro3.29
Canada1.60
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare6.89
Regeneron Pharmaceuticals IncHealthcareHealthcare6.42
Amgen IncHealthcareHealthcare5.95
Gilead Sciences IncHealthcareHealthcare5.74
AstraZeneca PLCHealthcareHealthcare3.64
Candriam Equities L Biotechnology Class I EUR Hedged Cap

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures